<DOC>
	<DOCNO>NCT03006575</DOCNO>
	<brief_summary>This Phase II randomize study determine efficacy consolidation chemotherapy split irradiation concurrent chemotherapy locoregional recurrence non-small cell lung cancer surgical resection</brief_summary>
	<brief_title>Study Consolidation Chemotherapy For Locoregional Recurrence Of Non-small Cell Lung Cancer After Surgical Resection</brief_title>
	<detailed_description>This Phase II randomize study determine efficacy consolidation chemotherapy ( CC ) split-course chemoradiotherapy ( CCRT ) locoregional recurrence non-small cell lung cancer surgical resection . Patients randomly assign either CCRT alone ( observation arm ) CCRT follow CC ( consolidation arm ) . All patient receive four cycle weekly docetaxel ( 25mg/㎡ ) nedaplatin ( 25mg/㎡ ) ( DP ) , 1 day 's duration , combine split-course thoracic radiotherapy 51 Gy/17 fraction 15 Gy/5 fraction administer first second course , respectively , one-month break . In consolidation arm , patient treat two cycle pemetrexed ( 500mg/㎡ ) non-squamous lung cancer docetaxel ( 60mg/㎡ ) squamous lung cancer , 3 day ' duration , every 3 week . The primary end point progression-free survival , time pass first day radiotherapy date disease progress . Progression-free survival calculate compare use Kaplan-Meier method . Toxicities grade accord CTCAE v. 4.0 .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Pathologic confirmation NSCLC . Patients measurable evaluable lesion base Response Evaluation Criteria Solid Tumors ( RECIST ) criterion . Postoperative locoregional recurrence include ipsilateral hemithorax mediastinum . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 . Previously treat chemotherapy treatmentnaive No previous chest radiotherapy , immunotherapy biotherapy Hemoglobin≥10 mg/dL , platelet≥100000/μL , absolute neutrophil count ≥1500/μL Serum creatinine ≤1.25 time upper normal limit ( UNL ) , creatinine clearance≥60 ml/min Bilirubin ≤1.5 time UNL , AST（SGOT）≤2.5 time UNL , ALT（SGPT）≤2.5 time UNL , alkaline phosphatase ≤5 time UNL Forced expiratory volume one second ( FEV1 ) &gt; 0.8 L Coagulation test within normal limit patient family sign informed consent Previous recent another malignancy , except nonmelanoma skin cancer cervical cancer situ Second primary carcinoma lung Contraindication chemotherapy Malignant pleural pericardial effusion . Women pregnancy , lactation period , pregnancy test 14 day first dos Women probability pregnancy without contraception Tendency hemorrhage In clinical trial within 30 day Addicted drug alcohol , AIDS patient Uncontrollable seizure psychotic patient without selfcontrol ability Severe allergy idiosyncrasy Not suitable study judge researcher</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>Split-course Chemoradiotherapy</keyword>
	<keyword>Locoregional recurrence</keyword>
	<keyword>Postoperative recurrence</keyword>
	<keyword>Consolidation chemotherapy</keyword>
</DOC>